New Patents v

A compound having the formula: See Patent for Chemical Structure wherein R I is halogen or a substituted or unsubstituted hydrocarbon group; R2R6 and R7, which may be the same or different, each represents hydrogen or a sub- stituted or unsubstituted hydrocarbon group, or R6 and R7 taken together may represent a hetero group having one or more hetero atoms; R3 and R4 which may be the same or different each represents a substituted or unsubstituted hydrocarbon group; or R3 and R4 taken together may represent an alkylene group or a hetero group having one or more hereto atoms and R5 is hydrogen, a substituted or unsub- stituted hydrocarbon group, halogen or a free or protected hydroxy group, or a pharmaceutically acceptable salt thereof. The compounds have antiaggregating properties.

4 8 1 0 4 8 9

H I G H O I L P H A S E P H A R M A C E U T I C A L V E H I C L E S

A N D S U N S C R E E N C O M P O S I T I O N S ; H A V I N G

W A T E R P R O O F S U N P R O T E C T I O N F A C T O R S

Terrence Murray, Bhiku Patel, Richard O Muhl- hauser assigned to Bristol-Myers Company

High oil phase pharmaceutical vehicles in the form of an emulsion system having an oil phase content of from about 35% to about 65%, wherein the emulsion system comprises from ab- out 1% to about 10% of an alkylated PVP copolymer, from about 2% to about 10% of an emulsifier, and a solvent system. The solvent sys- tern comprises from about 4% to about 20~ of a C4-C22 fatty acid, alcohol or ester thereof, from about 2% to about 25% of a glycol ester or diester, and from 0% to about 13% of a branched chain ester of a C4-C22 carboxylic acid. The pharmaceutical vehicles are useful in sunscreen formulations, and especially those containing higher concentrations of benzophenone-3. When such higher concentrations are used, it is advantageous to add up to about 10% of a branched chain ester of a C4-C22 carboxylic acid.

4 8 1 0 4 9 7

P H A R M A C E U T I C A L C O M P O S I T I O N S

David F Horrobin, Haslemere, United Kingdom assigned to Efamol Limited

Presenile and senile dementia, in particular Alz- heimer's disease, can be combated or alleviated by administration of an effective amount of a physiologically acceptable lithium compound and an essential fatty acid or a physiologically acceptable salt thereof.

4810501

S U S T A I N E D R E L E A S E P H A R M A C E U T I C A L

P R E P A R A T I O N S

Isaac Ghebre-Sellassie, Russell U Nesbitt, Uma Iyer, Mahdi Fawzi assigned to Warner-Lambert Company

Sustained release solid dosage forms-i.e., tablets, pellets, granules, and powders-can be made using a combination of polymeric and ionic par- ticulate materials to modify release profiles, per- meability and processability.

4 8 1 0 6 9 2

I M M U N O S U P P R E S S A N T S U B S T A N C E S , P R O C E S S F O R

T H E I R P R E P A R A T I O N A N D P H A R M A C E U T I C A L

C O M P O S I T I O N S C O N T A I N I N G T H E M

Maurice Deschamps, Francois Floc'h, Gerard Jung, Rodoiphe Margraff, Saint Maur, France assigned to Rhone-Poulenc Sante

The invention provides two novel immuno- suppressant cyclodepsipeptides of formula: See Patent for Chemical Structure in which X is chlorine or hydrogen. These compounds may be made by culturing Streptomyces sp. S-16328 (CBS 162.86). The compound in which X is chlorine may be hydrogenolysed to give the com- pound in which X is hydrogen,

4 8 1 0 6 9 7

P H A R M A C E U T I C A L F O R M U L A

Peter Speiser, M Orhan Vaizoglu, CH 8044 Zswitzerlana

The present invention concerns a pharma- cological vehicle or carrier system, which makes possible administration of the active ingredient with a high absorption thereof in the blood cir-